|
시장보고서
상품코드
2060244
마이코플라스마 검사 시장 분석 및 예측 : 유형, 제품 유형, 서비스, 기술, 용도, 프로세스, 최종 사용자, 솔루션(-2035년)Mycoplasma Testing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Solutions |
||||||
세계 마이코플라스마 검사 시장은 2025년 39억 달러에서 2035년까지 72억 달러로 성장하여 CAGR은 6.0%를 나타낼 것으로 예측됩니다. 이 시장은 적정 수준의 통합이 이루어져 있으며, 높은 정확도를 자랑하는 PCR 기반 검사법이 주류를 이루고 있습니다. 이 시장은 바이오의약품의 제조 및 연구 분야에서 매우 중요한 역할을 하고 있습니다. 시장 성장은 엄격한 규제 요건과 바이오의약품 생산 증가에 힘입어 이루어지고 있습니다. 각 기업은 신속하고 신뢰할 수 있는 검사 솔루션에 투자하고 있습니다. 전략적 제휴를 통해 기술력이 확대되고 있습니다. 오염 관리에 대한 수요 증가가 꾸준한 성장을 뒷받침하고 있습니다.
마이코플라스마 검사 시장에서 ‘a유형 a’ 부문은 키트 및 시약, 장비, 서비스로 분류됩니다. 이 중 키트 및 시약은 각 연구소에서 마이코플라스마 오염을 신속하고 정확하게 일상적으로 검출하는 데 필수적인 역할을 하고 있어 가장 큰 시장 점유율을 차지하고 있습니다. 이러한 제품들은 바이오의약품, 백신, 세포 유래 제품의 안전성과 유효성을 확보하기 위해 엄격한 품질 관리가 필수적인 제약 및 생명공학 업계에서 널리 사용되고 있습니다. 이 부문은 시약의 민감도와 사용 편의성이 지속적으로 개선되고 있는 데 더해, 워크플로우를 간소화하고 검사 효율을 높이는 즉시 사용 가능한 검사 키트의 도입이 확대됨에 따라 더욱 성장하고 있습니다.
마이코플라스마 검사 시장의 ‘기술’ 부문에는 PCR, ELISA, 직접법 및 기타 검출법이 포함되며, PCR이 주요 기술로 부상하고 있습니다. 이러한 우위는 높은 민감도와 특이성, 그리고 낮은 수준의 오염에서도 신속하고 신뢰할 수 있는 결과를 제공할 수 있는 능력에 기반을 두고 있습니다. PCR은 연구소나 바이오의약품 제조 현장에서 일상적인 선별 검사에 널리 활용되고 있습니다. 실시간 PCR 및 자동화 시스템 등의 기술적 진보로 인해 검출 정확도와 처리 능력이 향상되고 있습니다. 고급 분자진단법에 대한 수요가 증가하고 엄격한 규제 요건이 더해지면서, PCR 기반 검사법의 보급이 더욱 확대되고 있습니다.
지역별 개요
북미의 마이코플라스마 검사 시장은 첨단 바이오의약품 제조 기술과 엄격한 규제 체계에 힘입어 매우 성숙한 단계에 있습니다. 미국은 제품의 안전성과 품질을 확보하기 위해 PCR 기반 및 신속 검사 기술을 적극적으로 도입하고 있으며, 이 분야에서 선도적인 역할을 하고 있습니다. 캐나다 역시 생명공학 및 실험실 인프라에 대한 투자를 확대함으로써 시장에 기여하고 있습니다. 이 지역은 높은 연구개발비와 대형 제약사의 존재라는 혜택을 누리고 있습니다. 바이오의약품 생산 증가와 엄격한 오염 관리 요건이 수요를 지속적으로 견인하고 있으며, 검사 키트 및 자동화 분야의 지속적인 혁신이 시장 성장과 각 실험실의 업무 효율성을 한층 더 강화하고 있습니다.
아시아태평양의 마이코플라스마 검사 시장은 제약 생산의 확대와 품질 관리에 대한 관심 증가로 인해 급속한 성장을 이루고 있습니다. 중국과 인도 등의 국가들이 주요 기여국으로 자리 잡고 있으며, 이는 바이오기술 및 바이오시밀러 생산을 촉진하기 위한 정부의 이니셔티브에 힘입은 바 큽니다. 일본 또한 그 뛰어난 연구 역량을 바탕으로 중요한 역할을 수행하고 있습니다. CRO(의약품 개발 수탁 기관)에 대한 아웃소싱 증가와 오염 위험에 대한 인식 제고가 수요를 견인하고 있습니다. 의료 인프라 개선과 생명과학 연구에 대한 투자 확대가 시장 성장을 더욱 가속화하고 있으며, 이 지역은 마이코플라스마 검출 기술 분야의 검사 서비스 및 혁신을 위한 매력적인 거점으로 자리매김하고 있습니다.
주요 동향 및 촉진요인
마이코플라스마 검출 기술의 발전:
마이코플라스마 검사 시장에서는 PCR 및 차세대 염기서열 분석을 포함한 검출 방법의 기술적 발전에 대한 강력한 추세가 나타나고 있습니다. 이러한 기술은 바이오의약품 제조 과정에서 마이코플라스마 오염을 보다 신속하고 정확하게 식별할 수 있게 해줍니다. 감도 향상과 자동화를 통해 검사의 효율성과 신뢰성이 높아지고 있습니다. 검사 기관에서는 엄격한 품질 요건을 충족하기 위해 첨단 검출 시스템의 도입이 점점 더 확대되고 있습니다. 이러한 기술들이 비용 대비 효율성이 높아지고 널리 보급됨에 따라, 그 도입은 더욱 증가할 것으로 예상되며, 이는 시장 전체의 성장을 뒷받침하고 바이오의약품 제조 공정에서 제품의 안전성을 확보하는 데 기여할 것입니다.
바이오의약품 생산 확대:
바이오의약품 생산의 급속한 확대는 마이코플라스마 검사 시장의 주요 성장 동력입니다. 생물학적 제제, 백신, 세포 치료제에 대한 수요가 증가함에 따라, 마이코플라스마 검사를 포함한 엄격한 품질 관리 조치가 요구되고 있습니다. 제조업체는 규제 기준을 충족하기 위해 오염 없는 생산을 보장해야 합니다. 생명공학 기업의 성장과 조사 활동의 활성화는 검사 솔루션에 대한 수요를 더욱 촉진하고 있습니다. 또한, 바이오의약품 제조 시설에 대한 투자 증가도 시장 확대를 뒷받침하고 있습니다. 바이오의약품 생산 분야에서 품질 보증에 대한 이러한 수요가 증가함에 따라, 전 세계적으로 마이코플라스마 검사의 도입이 크게 촉진되고 있습니다.
목차
제1장 주요 요약
제2장 시장 하이라이트
제3장 시장 역학
제4장 부문 분석
제5장 지역별 분석
제6장 시장 전략
제7장 경쟁 정보
제8장 기업 개요
제9장 당사에 대해
JHSThe global Mycoplasma Testing Market is projected to grow from $3.9 billion in 2025 to $7.2 billion by 2035, at a compound annual growth rate (CAGR) of 6.0%. This market is moderately consolidated, with PCR-based assays leading due to high accuracy. It is critical in biopharmaceutical manufacturing and research. Growth is driven by strict regulatory requirements and increasing biologics production. Companies invest in rapid and reliable testing solutions. Strategic collaborations expand technological capabilities. Rising demand for contamination control supports steady growth.
In the Mycoplasma Testing Market, the aTypea segment is categorized into kits & reagents, instruments, and services. Among these, kits & reagents hold the largest share due to their essential role in enabling rapid, accurate, and routine detection of mycoplasma contamination across laboratories. These products are widely used in pharmaceutical and biotechnology industries, where strict quality control is mandatory to ensure the safety and efficacy of biologics, vaccines, and cell-based products. The segment is further supported by continuous advancements in reagent sensitivity and ease of use, along with the growing adoption of ready-to-use testing kits that streamline workflows and improve testing efficiency.
| Market Segmentation | |
|---|---|
| Type | PCR Assay, ELISA, Direct Assay, Indirect Assay, Microbial Culture Techniques, Enzymatic Methods, DNA Staining, Others |
| Product | Instruments, Kits & Reagents, Software & Services, Consumables, Others |
| Services | Testing Services, Consultation Services, Training Services, Others |
| Technology | Molecular Diagnostics, Cell Culture Techniques, Immunological Methods, Others |
| Application | Cell Line Testing, Virus Testing, End-Product Testing, Biopharmaceutical Production, Research & Academic Applications, Diagnostic Applications, Others |
| Process | Sample Preparation, Detection, Data Analysis, Others |
| End User | Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Diagnostic Laboratories, Others |
| Solutions | Automated Testing Solutions, Manual Testing Solutions, Others |
The aTechnologya segment of the Mycoplasma Testing Market includes PCR, ELISA, direct assays, and other detection methods, with PCR emerging as the dominant technology. Its leadership is driven by its high sensitivity, specificity, and ability to deliver rapid and reliable results, even at low contamination levels. PCR is extensively utilized in research laboratories and biopharmaceutical manufacturing for routine screening. Technological advancements, such as real-time PCR and automated systems, are enhancing detection accuracy and throughput. The increasing demand for advanced molecular diagnostics and stringent regulatory requirements further contribute to the widespread adoption of PCR-based testing methods.
Geographical Overview
The Mycoplasma Testing Market in North America is highly mature, supported by advanced biopharmaceutical manufacturing and stringent regulatory frameworks. The United States leads the region with strong adoption of PCR-based and rapid testing technologies to ensure product safety and quality. Canada also contributes with growing investments in biotechnology and laboratory infrastructure. The region benefits from high R&D expenditure and the presence of major pharmaceutical companies. Increasing biologics production and strict contamination control requirements continue to drive demand, while continuous innovation in testing kits and automation further strengthens market growth and operational efficiency across laboratories.
The Asia-Pacific Mycoplasma Testing Market is experiencing rapid growth due to expanding pharmaceutical manufacturing and increasing focus on quality control. Countries such as China and India are key contributors, supported by government initiatives promoting biotechnology and biosimilars production. Japan also plays a significant role due to its advanced research capabilities. Rising outsourcing to contract research organizations and growing awareness of contamination risks are driving demand. Improvements in healthcare infrastructure and increasing investments in life sciences research are further accelerating market expansion, making the region an attractive hub for testing services and innovation in mycoplasma detection technologies.
Key Trends and Drivers
Technological Advancements in Mycoplasma Detection:
The mycoplasma testing market is experiencing a strong trend toward technological advancements in detection methods, including PCR and next-generation sequencing. These technologies offer faster, more accurate identification of mycoplasma contamination in biopharmaceutical production. Improved sensitivity and automation are enhancing testing efficiency and reliability. Laboratories are increasingly adopting advanced detection systems to meet stringent quality requirements. As these technologies become more cost-effective and widely available, their adoption is expected to increase, supporting overall market growth and ensuring product safety in biopharmaceutical manufacturing processes.
Growth in Biopharmaceutical Production:
The rapid expansion of biopharmaceutical production is a key driver of the mycoplasma testing market. Increasing demand for biologics, vaccines, and cell-based therapies requires stringent quality control measures, including mycoplasma testing. Manufacturers must ensure contamination-free production to meet regulatory standards. The growth of biotechnology companies and research activities is further boosting demand for testing solutions. Additionally, rising investments in biopharma manufacturing facilities are supporting market expansion. This growing need for quality assurance in biologics production is significantly driving the adoption of mycoplasma testing globally.
Research Scope
- Estimates and forecasts the overall market size across type, application, and region.
- Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
- Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
- Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
- Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
- Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
- Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.
TABLE OF CONTENTS
1 Executive Summary
- 1.1 Market Size and Forecast
- 1.2 Market Overview
- 1.3 Market Snapshot
- 1.4 Regional Snapshot
- 1.5 Strategic Recommendations
- 1.6 Analyst Notes
2 Market Highlights
- 2.1 Key Market Highlights by Type
- 2.2 Key Market Highlights by Product
- 2.3 Key Market Highlights by Services
- 2.4 Key Market Highlights by Technology
- 2.5 Key Market Highlights by Application
- 2.6 Key Market Highlights by End User
- 2.7 Key Market Highlights by Process
- 2.8 Key Market Highlights by Solutions
3 Market Dynamics
- 3.1 Macroeconomic Analysis
- 3.2 Market Trends
- 3.3 Market Drivers
- 3.4 Market Opportunities
- 3.5 Market Restraints
- 3.6 CAGR Growth Analysis
- 3.7 Impact Analysis
- 3.8 Emerging Markets
- 3.9 Technology Roadmap
- 3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis
4 Segment Analysis
- 4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 PCR Assay
- 4.1.2 ELISA
- 4.1.3 Direct Assay
- 4.1.4 Indirect Assay
- 4.1.5 Microbial Culture Techniques
- 4.1.6 Enzymatic Methods
- 4.1.7 DNA Staining
- 4.1.8 Others
- 4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Instruments
- 4.2.2 Kits & Reagents
- 4.2.3 Software & Services
- 4.2.4 Consumables
- 4.2.5 Others
- 4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Testing Services
- 4.3.2 Consultation Services
- 4.3.3 Training Services
- 4.3.4 Others
- 4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Molecular Diagnostics
- 4.4.2 Cell Culture Techniques
- 4.4.3 Immunological Methods
- 4.4.4 Others
- 4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Cell Line Testing
- 4.5.2 Virus Testing
- 4.5.3 End-Product Testing
- 4.5.4 Biopharmaceutical Production
- 4.5.5 Research & Academic Applications
- 4.5.6 Diagnostic Applications
- 4.5.7 Others
- 4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Pharmaceutical Companies
- 4.6.2 Biotechnology Companies
- 4.6.3 Contract Research Organizations
- 4.6.4 Academic Research Institutes
- 4.6.5 Diagnostic Laboratories
- 4.6.6 Others
- 4.7 Market Size & Forecast by Process (2020-2035)
- 4.7.1 Sample Preparation
- 4.7.2 Detection
- 4.7.3 Data Analysis
- 4.7.4 Others
- 4.8 Market Size & Forecast by Solutions (2020-2035)
- 4.8.1 Automated Testing Solutions
- 4.8.2 Manual Testing Solutions
- 4.8.3 Others
5 Regional Analysis
- 5.1 Global Market Overview
- 5.2 North America Market Size (2020-2035)
- 5.2.1 United States
- 5.2.1.1 Type
- 5.2.1.2 Product
- 5.2.1.3 Services
- 5.2.1.4 Technology
- 5.2.1.5 Application
- 5.2.1.6 End User
- 5.2.1.7 Process
- 5.2.1.8 Solutions
- 5.2.2 Canada
- 5.2.2.1 Type
- 5.2.2.2 Product
- 5.2.2.3 Services
- 5.2.2.4 Technology
- 5.2.2.5 Application
- 5.2.2.6 End User
- 5.2.2.7 Process
- 5.2.2.8 Solutions
- 5.2.3 Mexico
- 5.2.3.1 Type
- 5.2.3.2 Product
- 5.2.3.3 Services
- 5.2.3.4 Technology
- 5.2.3.5 Application
- 5.2.3.6 End User
- 5.2.3.7 Process
- 5.2.3.8 Solutions
- 5.2.1 United States
- 5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
- 5.3.1.1 Type
- 5.3.1.2 Product
- 5.3.1.3 Services
- 5.3.1.4 Technology
- 5.3.1.5 Application
- 5.3.1.6 End User
- 5.3.1.7 Process
- 5.3.1.8 Solutions
- 5.3.2 Argentina
- 5.3.2.1 Type
- 5.3.2.2 Product
- 5.3.2.3 Services
- 5.3.2.4 Technology
- 5.3.2.5 Application
- 5.3.2.6 End User
- 5.3.2.7 Process
- 5.3.2.8 Solutions
- 5.3.3 Rest of Latin America
- 5.3.3.1 Type
- 5.3.3.2 Product
- 5.3.3.3 Services
- 5.3.3.4 Technology
- 5.3.3.5 Application
- 5.3.3.6 End User
- 5.3.3.7 Process
- 5.3.3.8 Solutions
- 5.3.1 Brazil
- 5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
- 5.4.1.1 Type
- 5.4.1.2 Product
- 5.4.1.3 Services
- 5.4.1.4 Technology
- 5.4.1.5 Application
- 5.4.1.6 End User
- 5.4.1.7 Process
- 5.4.1.8 Solutions
- 5.4.2 India
- 5.4.2.1 Type
- 5.4.2.2 Product
- 5.4.2.3 Services
- 5.4.2.4 Technology
- 5.4.2.5 Application
- 5.4.2.6 End User
- 5.4.2.7 Process
- 5.4.2.8 Solutions
- 5.4.3 South Korea
- 5.4.3.1 Type
- 5.4.3.2 Product
- 5.4.3.3 Services
- 5.4.3.4 Technology
- 5.4.3.5 Application
- 5.4.3.6 End User
- 5.4.3.7 Process
- 5.4.3.8 Solutions
- 5.4.4 Japan
- 5.4.4.1 Type
- 5.4.4.2 Product
- 5.4.4.3 Services
- 5.4.4.4 Technology
- 5.4.4.5 Application
- 5.4.4.6 End User
- 5.4.4.7 Process
- 5.4.4.8 Solutions
- 5.4.5 Australia
- 5.4.5.1 Type
- 5.4.5.2 Product
- 5.4.5.3 Services
- 5.4.5.4 Technology
- 5.4.5.5 Application
- 5.4.5.6 End User
- 5.4.5.7 Process
- 5.4.5.8 Solutions
- 5.4.6 Taiwan
- 5.4.6.1 Type
- 5.4.6.2 Product
- 5.4.6.3 Services
- 5.4.6.4 Technology
- 5.4.6.5 Application
- 5.4.6.6 End User
- 5.4.6.7 Process
- 5.4.6.8 Solutions
- 5.4.7 Rest of APAC
- 5.4.7.1 Type
- 5.4.7.2 Product
- 5.4.7.3 Services
- 5.4.7.4 Technology
- 5.4.7.5 Application
- 5.4.7.6 End User
- 5.4.7.7 Process
- 5.4.7.8 Solutions
- 5.4.1 China
- 5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
- 5.5.1.1 Type
- 5.5.1.2 Product
- 5.5.1.3 Services
- 5.5.1.4 Technology
- 5.5.1.5 Application
- 5.5.1.6 End User
- 5.5.1.7 Process
- 5.5.1.8 Solutions
- 5.5.2 France
- 5.5.2.1 Type
- 5.5.2.2 Product
- 5.5.2.3 Services
- 5.5.2.4 Technology
- 5.5.2.5 Application
- 5.5.2.6 End User
- 5.5.2.7 Process
- 5.5.2.8 Solutions
- 5.5.3 United Kingdom
- 5.5.3.1 Type
- 5.5.3.2 Product
- 5.5.3.3 Services
- 5.5.3.4 Technology
- 5.5.3.5 Application
- 5.5.3.6 End User
- 5.5.3.7 Process
- 5.5.3.8 Solutions
- 5.5.4 Spain
- 5.5.4.1 Type
- 5.5.4.2 Product
- 5.5.4.3 Services
- 5.5.4.4 Technology
- 5.5.4.5 Application
- 5.5.4.6 End User
- 5.5.4.7 Process
- 5.5.4.8 Solutions
- 5.5.5 Italy
- 5.5.5.1 Type
- 5.5.5.2 Product
- 5.5.5.3 Services
- 5.5.5.4 Technology
- 5.5.5.5 Application
- 5.5.5.6 End User
- 5.5.5.7 Process
- 5.5.5.8 Solutions
- 5.5.6 Rest of Europe
- 5.5.6.1 Type
- 5.5.6.2 Product
- 5.5.6.3 Services
- 5.5.6.4 Technology
- 5.5.6.5 Application
- 5.5.6.6 End User
- 5.5.6.7 Process
- 5.5.6.8 Solutions
- 5.5.1 Germany
- 5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
- 5.6.1.1 Type
- 5.6.1.2 Product
- 5.6.1.3 Services
- 5.6.1.4 Technology
- 5.6.1.5 Application
- 5.6.1.6 End User
- 5.6.1.7 Process
- 5.6.1.8 Solutions
- 5.6.2 United Arab Emirates
- 5.6.2.1 Type
- 5.6.2.2 Product
- 5.6.2.3 Services
- 5.6.2.4 Technology
- 5.6.2.5 Application
- 5.6.2.6 End User
- 5.6.2.7 Process
- 5.6.2.8 Solutions
- 5.6.3 South Africa
- 5.6.3.1 Type
- 5.6.3.2 Product
- 5.6.3.3 Services
- 5.6.3.4 Technology
- 5.6.3.5 Application
- 5.6.3.6 End User
- 5.6.3.7 Process
- 5.6.3.8 Solutions
- 5.6.4 Sub-Saharan Africa
- 5.6.4.1 Type
- 5.6.4.2 Product
- 5.6.4.3 Services
- 5.6.4.4 Technology
- 5.6.4.5 Application
- 5.6.4.6 End User
- 5.6.4.7 Process
- 5.6.4.8 Solutions
- 5.6.5 Rest of MEA
- 5.6.5.1 Type
- 5.6.5.2 Product
- 5.6.5.3 Services
- 5.6.5.4 Technology
- 5.6.5.5 Application
- 5.6.5.6 End User
- 5.6.5.7 Process
- 5.6.5.8 Solutions
- 5.6.1 Saudi Arabia
6 Market Strategy
- 6.1 Demand-Supply Gap Analysis
- 6.2 Trade & Logistics Constraints
- 6.3 Price-Cost-Margin Trends
- 6.4 Market Penetration
- 6.5 Consumer Analysis
- 6.6 Regulatory Snapshot
7 Competitive Intelligence
- 7.1 Market Positioning
- 7.2 Market Share
- 7.3 Competition Benchmarking
- 7.4 Top Company Strategies
8 Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
- 8.2 Lonza Group
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
- 8.3 Merck KGaA
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
- 8.4 Charles River Laboratories
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
- 8.5 Sartorius AG
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
- 8.6 Bio-Rad Laboratories
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
- 8.7 Roche Diagnostics
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
- 8.8 Agilent Technologies
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
- 8.9 Promega Corporation
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
- 8.10 Becton Dickinson and Company
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
- 8.11 Takara Bio
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
- 8.12 ATCC
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
- 8.13 InvivoGen
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
- 8.14 Minerva Biolabs
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
- 8.15 Eurofins Scientific
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
- 8.16 GenBio
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
- 8.17 Creative Bioarray
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
- 8.18 Sigma-Aldrich
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
- 8.19 Mycoplasma Experience
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
- 8.20 Norgen Biotek
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis
9 About Us
- 9.1 About Us
- 9.2 Research Methodology
- 9.3 Research Workflow
- 9.4 Consulting Services
- 9.5 Our Clients
- 9.6 Client Testimonials
- 9.7 Contact Us
